New device aims to stop deadly infections in tiny preemies

NCT ID NCT02633124

Terminated Prevention Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a special multi-line device (Edelvaiss Multiline NEO) to see if it could prevent bloodstream infections in very premature infants (24-29 weeks) who need IV medications and nutrition. The device was compared to standard infusion sets. Unfortunately, the trial was stopped early, so we don't have clear answers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Edelvaiss Multiline NEO device
What this could lead to: If proven effective, this device could reduce dangerous bloodstream infections in premature babies, shortening hospital stays and saving lives.
What could go wrong: The trial was terminated early with only 87 participants, so we don't have enough data to know if the device works. It may not be better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BACTEREMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bacterial infectious disease with sepsis Premature Birth

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BACTEREMIA INFANT, VERY LOW BIRTH WEIGHT

Contacts and locations

Locations

Chu Amiens Picardie

Amiens, France
Hôpital Charles Nicolle - CHU de Rouen

Rouen, France
Hôpital Côte de Nacre - CHU de Caen

Caen, France
Hôpital Jeanne de Flandre - CHRU de Lille

Lille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.